In abstinent alcoholics, stress induces negative affect-a response linked to craving and relapse. In rats, repeated stresses at weekly intervals prior to 5-day ethanol diet sensitize withdrawal-induced anxiety-like behavior ("anxiety") that is blocked by a CRF1-receptor antagonist. Current experiments were performed to identify brain sites that support CRF involvement in stress sensitization of ethanol withdrawal-induced anxiety- 
Introduction
Considerable evidence supports involvement of corticotrophin releasing factor (CRF), a 41 amino acid peptide (Vale et al., 1981) , in stress (Bale and Vale, 2004; Koob and Heinrichs, 1999) , in production of anxiety (Spina et al., 2002) , as well as in the expression of anxiety-like behavior ("anxiety") during withdrawal from chronic ethanol (Baldwin et al., 1991; Overstreet et al., 2004) . Previous work demonstrated that repeated stresses prior to 5-day chronic ethanol diet (stress/withdrawal protocol) sensitized anxiety during withdrawal . Subsequently, a CRF-1 receptor antagonist prevented this sensitization , whereas repeated intracerebroventricular (ICV) administrations of CRF prior to ethanol exposure substituted for stress to induce sensitization . Since it has been shown that corticosterone induced by CRF activation of the hypothalamic pituitary adrenal (HPA) axis was not responsible for the stress/withdrawal-induced sensitization , these efforts provided critical support for an extrahypothalamic action of CRF being responsible for the sensitization.
An important aspect not previously explored is the neuroanatomical basis of CRF involvement in the repeated stress sensitization. CRF (Cummings et al., 1983;  JPET #159186 stress/withdrawal protocol sensitization of anxiety could be confirmed. Several brain regions known to be associated with anxiety-like behavior, including the central nucleus of the amygdala (CeA), the basolateral amygdala (BLA), the dorsal raphe nucleus (DRN) and the bed nucleus of the stria terminalis (BNST) contain CRF (Cummings et al., 1983; Swanson et al., 1983) and CRF receptors (De Souza et al., 1995; Van Pett et al., 2000) . Because microinjection of a general CRF receptor antagonist into the CeA reversed the anxiogenic response to acute ethanol withdrawal (Baldwin et al., 1991; Rassnick et al., 1993) , this site was the first to be chosen for investigation. The DRN was chosen because this site has been shown to have an association with sensitization of anxiety induced by repeated withdrawals (Overstreet et al. 2006) . The BNST was chosen because it is linked to the amygdala (Dong et al, 2001 ) and has an association with fear and anxiety associated behaviors (Davis et al., 1997; Lee et al., 2008; Sahuque et al., 2006) . In addition to these brain sites, the paraventricular nucleus (PVN) of the hypothalamus and the CA1-region of the hippocampus were tested with CRF. The PVN is a critical brain site for control of the HPA axis (Rivier et al., 1983) and also contains CRF (Swanson et al., 1983) and CRF receptors (De Souza et al., 1995; Van Pett et al., 2000) , but has not been associated with anxiety-like behavior. The CA1-hippocampal region was chosen as it has neural interactions with the amygdala (Akirav and Richter-Levin, 1999; Sheth et al., 2008) and there are CRF receptors present at this site (De Souza et al., 1995; Van Pett et al., 2000) .
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Even though CRF reportedly has approximately a 17 fold greater affinity for CRF-1 receptors than CRF-2 receptors (Vaughan et al., 1995; Hauger et al, 2003) , we sought to confirm previous evidence for CRF-1 receptor involvement in the CRF/withdrawal and stress/withdrawal protocols. Testing for involvement of specific CRF-receptor subtypes in sensitization of withdrawal-induced anxiety was identified by administering a CRF1-receptor antagonist systemically prior to repeated CRF microinjection or by substituting urocortin-3, a CRF-2 receptor agonist (Lewis et al., 2001) , for CRF microinjection into selected brain sites prior to the 5 days of ethanol diet. Urocortin-3 has virtually no effect on CRF1 receptors. Additionally, to confirm the involvement of CRF-1 receptors in stress sensitization of withdrawalinduced anxiety , a CRF1-receptor antagonist was administered prior to each repeated stress application into sites where microinjected CRF was found to sensitize ethanol withdrawal-induced anxiety-like behavior.
Collectively, the present investigations sought to extend our understanding of the neuroanatomical basis of CRF involvement in the repeated stress sensitization of ethanol withdrawal-induced anxiety and document the CRF receptor subtype linked to this sensitization. Additionally, these data were expected to confirm that stress and CRF induce a cumulative maladaptation that is made apparent only when followed by ethanol exposure and withdrawal. with lights on at 7:00 AM and off at 7:00 PM). After acclimation, the rats underwent surgery as described below. After surgery the animals were individually housed and, after several days of recovery, were placed on a nutritionally complete lactalbumindextrose diet and ultimately microinjected centrally as per the strategies outlined. All procedures for the animals were approved by the Institutional Animal Care and Use Committee (IACUC) at the University of North Carolina at Chapel Hill.
Surgery for Cannula Implantation. Surgery to implant stainless steel cannulae into brain sites was performed under 2.5% isoflurane anesthesia. While anesthetized, a rat was placed in a stereotaxic frame (Kopf Instruments, Tujunga, CA). The dorsal surface of the skull was exposed and holes were drilled over the appropriate region for placement of the cannulae. The cannulae (26 gauge stainless steel tubing) were directed dorsal to the brain site being microinjected using coordinates from a rat atlas (Paxinos and Watson, 2005) . The rats received bilateral cannula implants over the central amygdala (CeA) (AP = -2.3, ML = -4.5, DV = -5.5), basolateral amygdala (BLA) (AP = -2.3, ML = -5, DV = -6), the CA1 region of the hippocampus (AP = -4, ML = -3, DV -1.5) and either the dorsal (AP = -0.24, ML = -1.6, DV = -2) or the ventral (AP = -4, ML = -3, DV = -1.5) bed nucleus of the stria terminalis (BNST). Additionally, unilateral cannulae were implanted above the lateral ventricle for the ICV injections (AP = -0.8, ML = -1.6, DV = -2). Because the dorsal raphe nucleus (DRN) (AP = +1.56 from lambda, ML = -3.5, DV = -4.94) and the paraventricular nucleus (PVN) of the This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on October 20, 2009 as DOI: 10.1124 at ASPET Journals on June 7, 2017 jpet.aspetjournals.org Downloaded from hypothalamus (AP = -1.88, ML = 3, DV = -6.5) are midline structures, bilateral injections were not needed. All injections were angled to these midline locations from the drill holes on the right side of the skull. Insertion angles were 30º for the DRN and 20.7º for the PVN. The distances from the cannula tips to the injection sites were as follows: CeA 2.5 mm, BLA 2.5 mm, DRN 2 mm, d-BNST 4.5 mm, v-BNST 4.5 mm, hippocampus 2 mm, PVN 2.05 mm, ICV 2.5 mm. Targeted brain sites and limits for acceptance of data are discussed below. Cannulae were secured to the skull with stainless steel screws and acrylic dental cement (Frye et al., 1984; Knapp et al., 2007; Overstreet et al., 2006) .
Once recovered from surgery, the rats were given acetaminophen (Children's Q-PAP, cherry flavored, 6 mg/ml) in the drinking water for 48 hrs. The rats were allowed to recover for at least 3 days before proceeding with further experimental procedures.
Procedures for Diet Administration. After the recovery period, the rats were given a nutritionally complete control liquid diet (Frye et al., 1984; Overstreet et al, 2002) . Rats received a calorically balanced and nutritionally complete control liquid diet for 12 days and were then placed on either a similar liquid diet containing 4.5% ethanol for 5 days or continued receiving the control diet (Overstreet et al, 2002) . Rats were weighed at weekly intervals, and volumes of diet were adjusted to ensure that groups within a given investigation gained weight similarly. Previous reports Overstreet et al., 2002) have demonstrated that this exposure to 4.5% ethanol diet produces blood ethanol levels of approximately 80-110 mg% prior to removal. The ethanol is reduced to near 0 by 5-6 hrs Overstreet et al., 2002) -the time at which behaviors related to social interaction are monitored (see below).
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Procedures for Microinjection of CRF and Urocortin-3 into Selected Brain
Regions on Sensitization of Ethanol Withdrawal-Induced Anxiety. Our laboratory prepares animals routinely for microinjection (Frye et al., 1984; Knapp et al., 2007; Overstreet et al., 2006) in a temporal sequence comparable to that employed with the repeated stress exposure protocol . The general protocol for treatment is illustrated in Figure   1 . CRF was administered into the CeA, BLA, DRN, d-BNST, v-BNST, CA1 of the hippocampus, or the PVN of the hypothalamus. Urocortin-3 was microinjected ICV or into the CeA, DRN, and d-BNST. The doses of CRF and urocortin-3 were dissolved in an artificial cerebrospinal fluid (aCSF) and delivered into each brain site through 32 gauge injectors placed into the implanted cannula guides. During placement of the injector needle into a given brain site, the animals were gently restrained in a cotton towel. The maximal dose of CRF was administered weekly into the CeA prior to 5 days of control diet to demonstrate a lack of effect of this treatment on social interaction. A 1 μl syringe delivered the 0.5 μl of the drug solution into each of the brain sites (per side if bilateral). Additionally, a urocortin-3 dose (5 μ g/5 μ l) was administered ICV into the ventricular cannula over a 1 min period using a 5 μl syringe. Urocortin-3 is active on CRF2 receptors with virtually no affinity for CRF1-receptors (Lewis et al., 2001 ). The injector remained in place for 1 min after the end of the infusion. Five days of 4.5% ethanol diet was initiated 24 hours after microinjection of CRF or urocortin-3 followed by determination of social interaction behavior during withdrawal from the ethanol as noted below.
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) was prepared as a suspension in 0.5% carboxymethylcellulose and elicited by the stress/withdrawal protocol , rats were treated with either the CRF1-receptor antagonist SSR125543 (10 µg/0.5 µl) or vehicle in each brain site 15 min before each stress session during exposure to the control liquid diet. The SSR125543 was dissolved in the aCSF containing 2.5% tween-80. The stress sessions consisted of restraining rats in plastic conical decapicones for 60 minutes on days 6 and 12. Either a single 5-day cycle of 4.5% ethanol diet was initiated 24 hrs after the final stress or control diet was continued . Social interaction changes were measured during withdrawal from ethanol diet as noted below.
Social Interaction Test.
The social interaction test was given 5 hours after the ethanol diet was withdrawn-a time at which the ethanol levels reach zero Overstreet et al., 2002) . In contrast to the original testing method of File (1980) that emphasized the score of the rat pair (see review by File and Seth, 2003) , the social interaction measure for this investigation utilized the behavior of each rat in the pair, as previously established (Overstreet et al., 2002 (Overstreet et al., , 2003 (Overstreet et al., 2002 ). An observer blind to treatments scored the time rats spent in active social contact. Behaviors monitored included sniffing, nipping, grooming, mounting, kicking, wrestling, jumping on, and crawling under or over the partner (File, 2003; Overstreet et al., 2002) . A locomotor activity score was also obtained based upon crossings over a grid (Overstreet et al., 2002) .
Histological Confirmation of Injection Sites.
To confirm appropriate placement, the cannula sites were defined histologically at the end of each experimental series. In this case, methyl green dye 0.5 μ l was microinjected into the brain site as described by Knapp et al (2007) using the same injectors used to microinject CRF, urocortin-3 and the CRF1-receptor antagonist. After euthanizing the rat, the brain was removed, frozen on dry ice, and stored at -80 ºC until sections were cut on a microtome to confirm the site of injection by an individual blind to the treatments. To provide a representation of placement of microinjections, supplementary material is provided noting the limits for acceptance. Since lowest dose of CRF was without effect in alcohol exposed rats, it would unlikely that lower doses would have an action in controls. Likewise, repeated vehicle microinjections prior to the 5 days of ethanol diet were without effect (ED-Vehicle).
These findings collectively demonstrate the need for the weekly doses of CRF to be given in combination with ethanol diet to produce the reflection of adaptive change (i.e., a reduction in social interaction). Additionally, consistent with previous data that have shown that social interaction scores for vehicle are equivalent to values in rats that do not receive central microinjections (Overstreet et al., 2002; Breese et al., 2004) , unpublished work showed that the social interaction score for CD-Vehicle was not different from that of rats that receive no surgery or vehicle. However, when results for repeated CRF administration into all of the brain sites prior to control diet was not deemed necessary. See Table 1 part 2 for the numbers of rats in each group and data illustrating no significant effect of treatments on locomotion during testing and the equal weight gain for these groups.
Repeated CRF Microinjections into the PVN of the Hypothalamus, v-BNST, or the CA1 Region of the Hippocampus do not Sensitize Ethanol Withdrawal-Induced
Anxiety.
In addition to the brain regions described above, CRF (0.5 Supplementary Data for for further information on these sites. As before, alcohol intake, body weights and locomotor activity for groups did not differ ( Table 1 part Previous work has demonstrated that CRF has greater affinity for and functional activity from CRF1 receptors than CRF2 receptors (Vaughn et al., 1995; Hauger et al., 2003) . are consistent with CRF action on CRF-1 receptors being critical to the sensitization induced from these brain sites. As before, locomotor activity, body weight, and alcohol intake were not significantly affected by any of these treatments (Table 1 part 4).
Lack of Effect of Urocortin-3 on Sensitization of Ethanol Withdrawal-Induced
To confirm the conclusion that CRF-1, but not CRF-2 receptors, were critical to the action of repeated CRF administration prior to ethanol diet, we tested whether antagonist given prior to ethanol has no effect on social interaction during withdrawal from 5 days of ethanol diet .
In agreement with results from
This article has not been copyedited and formatted. The final version may differ from this version. Breese, 1990 ) and sensitize withdrawal-induced anxiety-like behavior (Overstreet et al., 2002) . Subsequently, Overstreet et al. (2007) reported that a CRF1-receptor antagonist administration prior to the 1 st and 2 nd withdrawals of the multiple withdrawal protocol prevented sensitization of anxiety-like behavior by this protocol, an observation implicating CRF in the worsening symptoms of ethanol withdrawal from chronic exposure. Based upon a relationship of CRF to stress, it was reported that repeat stresses given prior to a single 5-day exposure to ethanol diet (stress/withdrawal protocol) substituted for repeated withdrawals to sensitize anxiety-like behavior ("anxiety") during withdrawal from a single 5 day exposure to chronic ethanol exposure that alone was without effect . To assess whether the stressinduced sensitization of withdrawal-induced anxiety was related to a central action of CRF, CRF was repeatedly administered intraventricularly (ICV) to substitute for the stress exposure prior to the 5 days of ethanol diet . This repeated ICV CRF administration sensitized withdrawal-induced anxiety-a finding suggesting that stress involves a central, not a peripheral mechanism, to induce this emotional change during ethanol withdrawal ). This conclusion is consistent with the finding that repeated peripheral administration of a glucocorticoid prior to chronic ethanol exposure does not sensitize withdrawal-induced anxiety .
The concept that a cumulative adaptation induced by the repeated chronic ethanol exposures was responsible for the negative consequences during withdrawal was initially proposed by Koob (2003) to be a change in allostasis-a concept consistent with that proposed by Ballenger and Post (1978) . The observation that CRF-1 receptor antagonist administration prior to the 1 st and 2 nd withdrawals of the multiple withdrawal protocols prevented sensitization of withdrawal-induced anxiety was consistent with this concept . In the present investigation a CRF-1 receptor antagonist administered prior to each of the stress and CRF applications also prevented sensitization of withdrawal-induced anxiety-like behavior.
These findings are consistent with the idea that both CRF and stress promote a cumulative adaptive mechanism that affects the subsequent magnitude of ethanol withdrawal-an adaptation that can also enhance the negative affect induced by a future stress during abstinence from ethanol (Breese et al., 2005a,b,c; Valdez et al., 2003) .
Because others demonstrated that CRF administered into the CeA was related to the anxiety-like behavior seen during ethanol withdrawal (Baldwin et al, 1991; Rassnick et al., 1993) , it was next considered whether this or other regions of brain were involved in the cumulative adaptation by stress and CRF that supported sensitization of ethanol withdrawal-induced anxiety-like behavior. When microinjected into the CeA, CRF as expected induced a dose-related sensitization of withdrawal-induced anxiety.
Furthermore, repeated CRF administrations into the BLA had a similar sensitizing effect as that for CRF microinjection into the CeA (Figures 2 & 4) . Collectively, the positive The tension-reduction hypothesis of alcoholism was published several decades ago to suggest that the consequence of stress per se increased alcohol drinking (Conger, 1956) ; however more recent studies Overstreet et al., 2007) raised the possibility that adaptation induced by stresses prior to a bout of alcohol abuse can also contribute to adaptive change much as repeated exposures to ethanol (Ballenger and Post, 1978; Overstreet et al., 2002) . Bale and Vale (2004) during withdrawal from chronic ethanol (Breese et al., , 2005a . In this respect, previous work has provided support for the conclusion that CRF contributes to adaptive change related to persistent alcohol exposure Heilig and Koob, 2007) . Furthermore, basic data ( Breese et al., 2005a,c) indicate that stress after chronic ethanol can precipitate negative affect, a response which one could speculate is comparable to the negative affect observed in the abstinent alcoholic that results in craving (Sinha, 2001 (Sinha, , 2008 Sinha et al., 2009 ). Both basic (Breese et al., 2005a,c) and clinical findings indicate that a CRF-1 receptor antagonist will prevent the negative consequences of stress after chronic ethanol exposure. Future investigations will be required to address whether chronic treatment of alcoholics administered a CRF-1 receptor antagonist could be a successful approach to minimize the increased susceptibility alcoholics display for increased craving to stress (Sinha, 2001 , Sinha et al., 2009 , Yoon et al., 2006 . Person to receive reprint requests: each site) and data for these vehicle injections were combined because a significant change across sites was not observed for these groups. When social interaction for the the CD-Vehicle group was compared to the ED-Vehicle group, no significant effect was observed (P> 0.05). A group that received CRF and were on control diet only was not included for each of the present sites because previous data demonstrated that ICV CRF to rats that received control diet does not induce sensitization ) and the repeated CRF in the CeA of control diet-treated animals likewise did not sensitize withdrawal-induced anxiety (Figure 2) . Social interaction was measured 5-6 hrs after the ethanol diet removal. The number of rats for each group is listed in Table 1 part 2.
Representative sites where CRF was microinjected are presented in prevented by the CRF1 receptor antagonist. Social interaction was measured 5-6 hrs after the ethanol diet removal. The number of rats for each group is listed in Table 1 part 4. In the CD-Vehicle group and the ED-Vehicle group, vehicle was administered into each of the brain sites (N = 4-6 for each site) and data were combined because a (7) 8.33±0.24 285±7 129±6 NS NS NS In the Treatments group column, the number in parentheses is the N per group. NS = No significant difference noted among the groups for any of the measures for each of the 6 treatments (Figures 2-7 This article has not been copyedited and formatted. The final version may differ from this version.
